Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update
by Amy Steele · The Cerbat GemBioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 10,300 shares, a drop of 86.7% from the December 15th total of 77,600 shares. Based on an average daily volume of 153,100 shares, the days-to-cover ratio is currently 0.1 days.
Bioxytran Stock Performance
BIXT traded down $0.00 during trading on Monday, reaching $0.10. The company had a trading volume of 136,712 shares, compared to its average volume of 394,173. Bioxytran has a 12-month low of $0.06 and a 12-month high of $0.15. The company has a market cap of $8.24 million, a price-to-earnings ratio of -9.50 and a beta of -0.55. The firm’s 50-day simple moving average is $0.09 and its 200 day simple moving average is $0.10.
Bioxytran Company Profile
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
Further Reading
- Five stocks we like better than Bioxytran
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- How to Invest in the FAANG Stocks
- Delta Can Fly to New Highs in 2025; Here’s Why